Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 23 rd Asia-Pacific Dermatology Conference Osaka, Japan.

Day 1 :

Keynote Forum

Danka Svecova

Comenius University, Slovakia

Keynote: Anti-IL-17 nanobody: A future option in treatment of psoriasis

Time : 09:00-09:40

OMICS International Dermatology Conference 2017 International Conference Keynote Speaker Danka Svecova photo
Biography:

Danka Svecova is presently a Professor of Dermatovenerology, Head of Bullous Disorders Unit, Department of Dermatovenerology, University Hospital and Faculty of Medicine, Comenius University, Slovakia. She is a Board Member of Committee for Dermatovenerology and Immunology dissertation for PhD at Comenius University and a Member of Committee for Probation of Specialization for Dermatovenerology at Comenius University and University of JP Safarik in Kosice. She has participated in research on Skin Allergology and Immunology under the supervision of Professor Akira Ohkawara at Hokkaido University in Sapporo, Japan. She wrote two monographs about blistering disorders-Pemphigus vulgaris autoimmune disease and Pemphigus.

Abstract:

An improved understanding of the pathogenesis of psoriasis has led to the development of multiple new potential targets for therapy. The first pathway targeted by new biologics focus on the p40 subunit that is shared by interleukin (IL)-12 and IL-23. Second new strategy focuses IL-17 or its receptor. Secukinumab is fully human monoclonal G1k antibody targeting IL-17A, approved in EU for the first-line systemic therapy of moderate-to-severe plaque psoriasis. New IL-17 inhibitors, Ixekizumab and Brodalumab achieved very good efficacy and are currently in administration approved review. We demonstrate the preliminary results of the anti-IL-17 A/F bispecific nanobody that neutralize the pro-inflammatory cytokines IL-17A and IL-17F. We present results of multicentric, phase I, randomized, double -blind, placebo controlled study investigated multiple ascending doses of anti-IL-17 A/F nanobody (M1095) in patients with moderate-to-severe psoriasis. Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) ≥12 and static Physician’s Global Assessment (sPGA) ≥3 were evaluated. Patients received 30, 60, 120 or 240 mg anti-IL-17 A/F nanobody or placebo every two weeks subcutaneously for 6 weeks. Primary endpoints were safety, tolerability, immunogenicity and pharmacokinetics. Secondary endpoints were pharmacodynamics, efficacy and histological analysis. On day 85, 6 weeks after the last dose of the drug, PASI 75 was achieved in 7/8 patients (88%) receiving 30 or 60 mg, 8/8 (100%) receiving 120 mg and 9/9 (100%) receiving 240 mg of drug. PASI 90 was achieved in 4/8 (50%), 7/8 (88%) and 9/9 (100%) patients receiving 30 mg, 60 mg, 120 mg or 240 mg, respectively. PASI 100 was achieved in 1/8 (13%), 2/8 (25%), 4/8 (50%) and 5/9 (56%) patients receiving 30 mg, 60 mg, 120 mg or 240 mg, respectively. Improved PASI scores were seen 7 days post-first dose in all 4 cohorts. Biopsy assessment of skin lesion showed complete reversal of disease pathology in majority of patients in high dose groups. Conclusion can be drawn that Anti-IL-17 A/F bispecific nanobody presents a new treatment option well tolerated and effective in patients with moderate-to-severe psoriasis associated with skin clearance improvement in all indices of psoriasis studied.

Keynote Forum

Tingsong Lim

Clique Clinic, Malaysia

Keynote: The facial overfilled syndrome

Time : 09:40-10:20

OMICS International Dermatology Conference 2017 International Conference Keynote Speaker Tingsong Lim photo
Biography:

Dr Tingsong Lim Medical Director of Clique Clinic Dr Tingsong Lim has actively involved in many academic research and training in Asian facial and body aesthetics, clinical application of fillers’ rheology, facial overfilled syndrome, pigmentary disorders, laser medicine and regenerative medicine. Graduated from Tohoku University School of Medicine under the Monbusho Scholarship, Dr Lim speaks 4 languages (English, Mandarin, Malay, Japanese) fluently, and has been a frequent speaker and trainer regionally and internationally. Medical Director of Clique Clinic, Dr Lim has a private practice in Kuala Lumpur, Malaysia.

Abstract:

As dermal fillers became more widely acceptable, we started to observe increasing numbers of people developing facial overfilled syndrome. These overfilled faces are commonly seen among those who have undergone multiple filler injections. The overfilled syndrome can be seen among those who had volume overload in the mid face, forehead, chin and nose. Incorrectly placed dermal fillers, poor selection of filler products, overzealous attempts by the injectors and overly enthusiastic clients who chase the lines are the common cause of this phenomenon. Many of those who have overfilled syndrome lost their original facial topography and may or may not be aware of such condition. The facial distortion can be exaggerated by facial expressions and movements. Overfilled syndrome is more commonly produced by practitioners depending solely on a single modality for treatment. Overfilled syndrome is commonly seen after multiple treatments with fillers. This syndrome is under-diagnosed and many practitioners are not aware of such condition. Having the awareness of the overfilled syndrome is crucial among aesthetic practitioners to prevent it from happening. Once a face is overfilled and the structure is distorted, diminishing the volume with hyaluronidase will help to minimize the distortion, but will not necessarily restore the face to its natural look. Therefore, it is very important for the medical aesthetic community to bring up the awareness of overfilled syndrome and prevent this from happening.